SUMMARY
patient consent were obtained. No patient had any evidence of gastrointestinal disease; none was taking any medication that would affect this system. Patients who could possibly be pregnant were excluded.
Patients were allocated randomly to receive, in a double-blind fashion, one of four premedications i.m.: group 1 = placebo only; group 2 = morphine 10 mg plus placebo; group 3 = morphine 10 mg plus cisapride 10 mg; group 4 = morphine 10 mg plus cisapride 4 mg.
Both cisapride preparations represented 2 ml of solution and the placebo was physiological saline 2 ml. The premedication was given into the right thigh using a 23-s.w.g. needle, 2 h before surgery.
Following premedication gastric emptying was assessed using the rate of absorption of orally administered paracetamol (Nimmo, Wilson and Prescott, 1975; Todd and Nimmo, 1983) . Paracetamol 1.5 g (three tablets) was taken with water 50 ml, 20 min after the injection of the premedication. Venous blood was obtained before the administration of the premedication, and then every 15 min for 90 min after the paracetamol. Plasma paracetamol concentrations were determined by high pressure liquid chromatography (Howie, Adriaenssens and Prescott, 1977) . Samples for the analysis of cisapride were taken at the same times and were analysed by high pressure liquid chromatography.
The rate of paracetamol absorption was estimated by the area under the plasma concentrationtime curve (AUC) at 45,60 and 90 min. Statistical analysis of these values, and of the paracetamol concentrations, was by Student's t test after logarithmic transformation of the data.
The peak paracetamol concentrations, and the time to achieve that peak, were compared between the groups using the Student's t test and the Mann-Whitney U test, respectively.
The groups were tested for significant differences, in respect of age, sex and weight, using the Chi-squared test and Student's t test.
Cisapride concentrations in groups 3 and 4 were compared using Student's t test.
Any adverse effects of the drug, especially nausea and vomiting, were noted.
BESULTS
There were no statistical differences between the groups with respect to age, sex and weight (table  I) .
No serious adverse effects were noted. One patient in group 4 complained of slight nausea for a short time, 50 min after the premedication of morphine 10 mg plus cisapride 4 mg. No patient vomited.
The mean paracetamol concentrations in the four groups are shown in figure 1 and table II.
There were significantly higher plasma paracetamol concentrations in the placebo group when compared with the morphine only group at 45,60, 75 and 90 min (P < 0.05). At these times, there were also significantly higher concentrations in the morphine plus cisapride 10 mg group when compared with the morphine only group (P < 0.05). There was no difference between the morphine plus cisapride 10 mg group and the placebo only group. After cisapride 4 mg, paracetamol concentrations did not differ from those in the morphine only group. The AUC obtained in the four groups at 45, 60 and 90 min are shown in table III.
FIG. 1. Paracetamol concentrations (mean±SEM). A---
The AUC 45, 60 and 90 min were significantly less in the morphine only group when compared with the placebo only group (P < 005). The AUC 45, 60 and 90 were significantly greater in the morphine plus cisapride 10 mg group when compared with the morphine only group (P < 0.05), but were not significantly different when the morphine plus cisapride 10 mg group was compared with the placebo only group. After morphine plus cisapride 4 mg, the AUC did not differ from those in the morphine only group. The peak paracetamol concentrations, and the times to achieve these peaks, are shown in table IV. There was a significantly lower peak paracetamol concentration in the morphine only group when compared with the control group (P < 0.01). Peak concentrations were significantly greater in the morphine plus cisapride 10 mg group when compared with the morphine only group (P < 0.05). Cisapride 4 mg failed to achieve this effect.
The time to peak concentrations showed a trend towards a delay in the morphine only group when compared with the control group and a reduction in the delay in the morphine plus cisapride 10 mg group. However, these differences failed to achieve statistical significance. There was a significant delay in the time to achieve peak concentrations in the morphine plus cisapride 4 mg group when compared with the control group (P < 0.01).
The mean plasma cisapride concentrations for groups 3 and 4 are shown in figure 2. The cisapride concentrations at every time were significantly greater in the cisapride 10 mg when compared with the cisapride 4 mg group (P < 0.01).
DISCUSSION
Morphine delayed the absorption of paracetamol presumably by inhibiting gastric emptying, as paracetamol is absorbed only after leaving the stomach. The addition of cisapride 4 mg to the morphine failed to prevent this delay. Similarly, metoclopramide 10 mg i.m. has been found to be ineffective in reversing the delay in gastric emptying caused by diamorphine and pethidine using the same methodology (Nimmo, Wilson and Prescott, 1975) .
Cisapride, in a dose of 10 mg i.m., prevented the delay in gastric emptying caused by morphine. This larger dose of cisapride was well tolerated by the patients and, in particular, no extrapyramidal side-effects were noted. This is to be expected as cisapride has been shown to be devoid of any anti-dopaminergic action (Reyntgens et aJ., 1984) .
The plasma cisapride concentrations show evidence of good absorption after i.m. administration and significantly greater concentrations of cisapride in the cisapride 10 mg group than in the 4 mg group.
No conclusions can be made as regards to the incidence of preoperative nausea and vomiting with cisapride as the numbers in this trial were too small. This question would be of importance if cisapride were to be used routinely with morphine as a premedication.
